Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes
Public ClinicalTrials.gov record NCT00424411. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin Therapy in Subjects With Type 2 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine, in subjects with Type 2 Diabetes Mellitus: 1. Whether glycemic control can be achieved at least as effectively with an insulin regimen involving pre-meal EXUBERA™ (inhaled insulin) plus a single bedtime Ultralente injection as with a conventional subcutaneous insulin regimen involving 2 mixed Regular/NPH insulin injections per day. 2. The toleration and safety of EXUBERA™ (inhaled insulin) therapy and its effects after 6 months, if any, on measures of pulmonary function.
Study identification
- NCT ID
- NCT00424411
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1999 (Type not available)
- Primary completion
- Not listed
- Completion
- Dec 2000 (Type not available)
- Last update posted
- Feb 13, 2007
1999 – 2000
United States locations
- U.S. sites
- 34
- U.S. states
- 17
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Burlingame | California | — | — |
| Pfizer Investigational Site | Irvine | California | — | — |
| Pfizer Investigational Site | Los Angeles | California | — | — |
| Pfizer Investigational Site | Newport Beach | California | — | — |
| Pfizer Investigational Site | Orange | California | — | — |
| Pfizer Investigational Site | San Diego | California | — | — |
| Pfizer Investigational Site | San Francisco | California | — | — |
| Pfizer Investigational Site | Tustin | California | — | — |
| Pfizer Investigational Site | New Haven | Connecticut | — | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | — | — |
| Pfizer Investigational Site | Clearwater | Florida | — | — |
| Pfizer Investigational Site | Miami | Florida | — | — |
| Pfizer Investigational Site | Tampa | Florida | — | — |
| Pfizer Investigational Site | Chicago | Illinois | — | — |
| Pfizer Investigational Site | Louisville | Kentucky | — | — |
| Pfizer Investigational Site | New Orleans | Louisiana | — | — |
| Pfizer Investigational Site | Columbia | Missouri | — | — |
| Pfizer Investigational Site | St Louis | Missouri | — | — |
| Pfizer Investigational Site | Omaha | Nebraska | — | — |
| Pfizer Investigational Site | New Hyde Park | New York | — | — |
| Pfizer Investigational Site | New York | New York | — | — |
| Pfizer Investigational Site | Rochester | New York | — | — |
| Pfizer Investigational Site | Durham | North Carolina | — | — |
| Pfizer Investigational Site | Greenville | North Carolina | — | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | — | — |
| Pfizer Investigational Site | Cleveland | Ohio | — | — |
| Pfizer Investigational Site | Portland | Oregon | — | — |
| Pfizer Investigational Site | Austin | Texas | — | — |
| Pfizer Investigational Site | Dallas | Texas | — | — |
| Pfizer Investigational Site | Irving | Texas | — | — |
| Pfizer Investigational Site | San Antonio | Texas | — | — |
| Pfizer Investigational Site | Burlington | Vermont | — | — |
| Pfizer Investigational Site | Charlottesville | Virginia | — | — |
| Pfizer Investigational Site | Renton | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00424411, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 13, 2007 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00424411 live on ClinicalTrials.gov.